Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McGahan, L. Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2017 Authors' conclusions Overall, ceritinib increased PFS and duration of response in untreated ALK-positive NSCLC, regardless of the presence or absence of baseline BM, relative to platinum-based chemotherapy. Ceritinib also improved general QoL and prolonged time to deterioration of cancer-specific symptoms compared to chemotherapy. However, results from the ASCEND-4 (phase III) open-label, randomised, multicentre trial hold limited external validity as crizotinib is now standard care over chemotherapy for ALK-positive NSCLC and it is unclear whether increased PFS actually confers a meaningful change in OS. Comparative studies of other second- and third-generation ALK inhibitors are ongoing which may offer further first-line options. Indexing Status Subject indexing assigned by CRD MeSH Carcinoma, Non-Small-Cell Lung; Humans; ceritinib Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 AccessionNumber 32017000331 Date abstract record published 01/08/2017 |